The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1362
April 18, 2011
View Complete Issue         Table of Contents 2019 
Transdermal Buprenorphine (Butrans) for Chronic Pain
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Transdermal Buprenorphine (Butrans) for Chronic Pain
April 18, 2011 (Issue: 1362)
The FDA has approved the partial opioid agonist buprenorphine in a transdermal formulation (Butrans – Purdue) for treatment of moderate to severe chronic pain. Buprenorphine has been available in the US for years in parenteral formulations for...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Transdermal Buprenorphine (Butrans) for Chronic Pain
Article code: 1362d
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.